Kisspeptin-54
Get a source-linked, educational explanation from this profile.
Complete Research Guide
Open each section for the available evidence. Gaps are stated rather than inferred.
Overview
Kisspeptin-54 is listed as hormonal / kisspeptin.
- •Reproductive axis stimulation (research)
- •Libido and arousal research
Regulatory status: Investigational — not approved.
Structure & Properties
Compound: Kisspeptin-54; also known as Metastin.
Pharmacologic class: Hormonal / Kisspeptin.
Known delivery routes: Subcutaneous, Intravenous.
Sequence, molecular weight, salt form, and excipient details are formulation-specific and are not listed unless verified by a manufacturer or laboratory COA.
How It Works
KISS1R agonist upstream of GnRH neurons; drives a physiologic GnRH pulse and downstream LH/FSH release.
- •Physiologic LH pulse without receptor downregulation
- •Signals in sexual-desire research
Human Research
Evidence grade: Clinical RCT (Limited)
Clinical RCT (Limited). Academic human trials in fertility and HSDD.
Laboratory Research
Academic human trials in fertility and HSDD
Preclinical findings describe biological plausibility, not proven benefit in people. Animal and laboratory doses do not translate directly to human use.
Processing & Interactions
Timing and exposure
No strict time-of-day requirement. Dose consistently at the same time daily and rotate injection sites. Follow the per-peptide dosing section above.
Potential interactions and combinations to avoid
- •Avoid stacking with peptides that share the same receptor or mechanism without clinical guidance.
- •Avoid combining with alcohol or immunosuppressants unless cleared by a clinician.
Absorption, half-life, metabolism, and clearance can vary by formulation and route. Use prescribing information when an approved product exists.
Safety & Precautions
Known or reported risks
- •Transient flushing/headache
- •Unknown chronic effects
- •Ovulation timing changes
Contraindications
- •Pregnancy
- •Hormone-sensitive malignancy
- •Hormone-sensitive cancer (prostate, breast, ovarian, uterine) without oncology direction
- •Undiagnosed abnormal uterine or vaginal bleeding
- •Pregnancy or possible pregnancy (fetal harm / ovarian hyperstimulation risk)
- •Precocious puberty or unresolved pituitary pathology
- •History of thromboembolism or ovarian hyperstimulation syndrome
- •Bleeding disorders or anticoagulant therapy without physician guidance (injection-site haematoma)
- •Active skin infection, cellulitis, or lipohypertrophy at intended injection sites
- •Inability to maintain sterile technique or safe sharps disposal
- •Not FDA-approved for human therapeutic use — no verified purity, sterility, or potency standards
- •Immunocompromised or transplant patients (unverified sterility and immunogenicity risk)
- •Concurrent participation in drug-tested sport (WADA prohibited or non-cleared substance)
- •Known hypersensitivity or prior reaction to this compound or any excipient/diluent
- •Pregnancy, attempting conception, or breastfeeding unless prescribed and monitored by a physician
- •Children and adolescents with open growth plates (unless under specialist endocrine care)
- •Active or recently treated malignancy without oncology clearance
- •Use without a confirmed diagnosis, baseline labs, and licensed clinical supervision
Unknown long-term toxicity should be assumed where controlled human data are limited. Seek urgent care for a severe or unexpected reaction.
Administration & Studied Formulations
Reference range: 0.1–1.0 nmol/kg (trial dosing)
Frequency: Single dose or infusion in trials
Cycling: Intermittent research dosing only.
Subcutaneous (SubQ)
Default route for most research and therapeutic peptides — best absorption for reconstituted powder.
31G × 5/16" insulin syringe (U-100). 100 units = 1 mL. Pinch skin at abdomen (2" from navel), outer thigh, or love handle. Insert at 45–90°. Rotate sites daily to prevent lipohypertrophy. Alcohol-swab site, air-dry, inject slow, hold 5 sec.
Intravenous (IV)
Clinician-administered only. Reserved for hospital protocols, senolytics research, or emergency use.
IV catheter / infusion pump. Sterile IV push or slow infusion per protocol. Not for home use.
Dosing information is educational context, not a personal recommendation. Approved products must follow their label and prescriber instructions.
Applications & Related Therapies
Potentially complementary measures
- •Most peptides pair safely with baseline nutrition, sleep, and resistance training.
Clinical use should account for diagnosis, approved alternatives, nutrition, activity, sleep, rehabilitation, current medicines, and appropriate monitoring.
Cases, Considerations & Ethics
Decision framework: establish the clinical goal, confirm evidence quality and legal status, screen contraindications and interactions, compare approved alternatives, define monitoring and stopping criteria, and use shared decision-making with a licensed clinician.
Case evidence: individual reports cannot establish safety or effectiveness and should not outweigh controlled trials.
Ethics: informed consent should distinguish established care from experimental use, disclose uncertainty and cost, avoid overstated claims, and never substitute research products for medically necessary care.
What is Kisspeptin-54?
In plain words
Kisspeptin-54, also called metastin, is a hormone-like peptide [a chain of amino acids]. It triggers signals that lead the body to release hormones involved in reproduction. Researchers study it for stimulating this hormone system, but clinical trial evidence is limited and it is not FDA-approved. Reported risks include brief flushing, headache, and changes in ovulation timing; long-term effects are unknown.
Technical definition
Kisspeptin-54, also known as metastin, is a hormonal peptide and KISS1R agonist acting upstream of gonadotropin-releasing hormone (GnRH) neurons. It drives a physiologic GnRH pulse and downstream release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), making it a research subject for reproductive axis stimulation. Evidence from clinical randomized controlled trials is limited; it remains investigational and is not FDA-approved.
Function
Dosing
Recommended Time of Day
Morning, fasted.
See “Timing & Interactions” below for full fasted/fed circumstances, what to avoid combining, and what pairs well.
Administration & Technique
Injection & Application Sites
- Abdomen — 2 in (5 cm) away from the navel, either side. Fastest, most consistent SubQ absorption.
- Flank / love handle — Lateral fat pad above the hip. Good rotation site when the abdomen is tender.
- Outer thigh — Upper outer quadrant, a hand-width below the hip. SubQ pinch at 45°.
- IV — clinician only — Antecubital vein or central line. Not for home administration.
Diagram is a general illustration, not a medical instruction. Rotate sites every injection, keep 1 in (2.5 cm) between recent sites, and avoid scars, moles, bruises and the navel area.
Cycling
Intermittent research dosing only.
Timing & Interactions
- ·Avoid stacking with peptides that share the same receptor or mechanism without clinical guidance.
- ·Avoid combining with alcohol or immunosuppressants unless cleared by a clinician.
- ·Most peptides pair safely with baseline nutrition, sleep, and resistance training.
Storage & Reconstitution
Reconstitution Calculator
1 mL = 100 units on a standard U-100 insulin syringe. Draw to the nearest 0.5 unit and confirm dosing with a clinician before injection.
Your Notes
Sign in to save personal notes on Kisspeptin-54 and sync them to Vial Lab.
Benefits
- ·Physiologic LH pulse without receptor downregulation
- ·Signals in sexual-desire research
Risks
- ·Transient flushing/headache
- ·Unknown chronic effects
- ·Ovulation timing changes
Contraindications
- ·Pregnancy
- ·Hormone-sensitive malignancy
- ·Hormone-sensitive cancer (prostate, breast, ovarian, uterine) without oncology direction
- ·Undiagnosed abnormal uterine or vaginal bleeding
- ·Pregnancy or possible pregnancy (fetal harm / ovarian hyperstimulation risk)
- ·Precocious puberty or unresolved pituitary pathology
- ·History of thromboembolism or ovarian hyperstimulation syndrome
- ·Bleeding disorders or anticoagulant therapy without physician guidance (injection-site haematoma)
- ·Active skin infection, cellulitis, or lipohypertrophy at intended injection sites
- ·Inability to maintain sterile technique or safe sharps disposal
- ·Not FDA-approved for human therapeutic use — no verified purity, sterility, or potency standards
- ·Immunocompromised or transplant patients (unverified sterility and immunogenicity risk)
- ·Concurrent participation in drug-tested sport (WADA prohibited or non-cleared substance)
- ·Known hypersensitivity or prior reaction to this compound or any excipient/diluent
- ·Pregnancy, attempting conception, or breastfeeding unless prescribed and monitored by a physician
- ·Children and adolescents with open growth plates (unless under specialist endocrine care)
- ·Active or recently treated malignancy without oncology clearance
- ·Use without a confirmed diagnosis, baseline labs, and licensed clinical supervision
Regulatory
Investigational — not approved
Veterinary Use (Pets)
No established veterinary protocol for Kisspeptin-54. Consult a licensed veterinarian before considering off-label use in any species.
Full veterinary reference →Functional Groups
Cited Works
Tap any study to open the published work.